Provided herein are compounds that activate IRE1/XBP1s, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for treating a subject having a disease or disorder that may be ameliorated by increasing IRE1/XBP1s activity.
由3-羟基-2-氨基吡啶和2,3-二溴丙酸乙酯获得3,4-二氢-2 H-吡啶并[3,2- b ] [1,4]恶嗪-2-羧酸乙酯衍生物。由内酰胺9得到的硫代内酰胺17的还原得到相应的乙基2 H-吡啶并[3,2- b ] [1,4]恶嗪-2-羧酸乙酯。将2-氯-3-氧代丙酸乙酯与2-氨基-3-羟基吡啶或3-氨基-4-羟基吡啶的使用分别导致了咪唑并[1,2- a ]吡啶衍生物或乙基吡啶基[4,3- b ] [1,4] -2-嗪嗪羧酸盐。
Ethyl 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-2-carboxylate derivatives were obtained from 3-hydroxy-2-aminopyridine and ethyl 2,3-dibromopropanoate. Reduction of thiolactam 17 obtained from the lactam 9 gave the corresponding ethyl 2H-pyrido[3,2-b][1,4]oxazine-2-carboxylate. The use of ethyl 2-chloro-3-oxopropanoate with 2-amino-3-hydroxypyridine or 3-amino-4-hydroxypyridine led, respectively, to
由3-羟基-2-氨基吡啶和2,3-二溴丙酸乙酯获得3,4-二氢-2 H-吡啶并[3,2- b ] [1,4]恶嗪-2-羧酸乙酯衍生物。由内酰胺9得到的硫代内酰胺17的还原得到相应的乙基2 H-吡啶并[3,2- b ] [1,4]恶嗪-2-羧酸乙酯。将2-氯-3-氧代丙酸乙酯与2-氨基-3-羟基吡啶或3-氨基-4-羟基吡啶的使用分别导致了咪唑并[1,2- a ]吡啶衍生物或乙基吡啶基[4,3- b ] [1,4] -2-嗪嗪羧酸盐。
CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS
申请人:[en]PROTEGO BIOPHARMA, INC.
公开号:WO2024118810A1
公开(公告)日:2024-06-06
Provided herein are compounds that activate IRE1/XBP1s, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for treating a subject having a disease or disorder that may be ameliorated by increasing IRE1/XBP1s activity.